Answers are grounded in this paper and cite their sources.
Nucleos(t)ide analogues (NAs) as the first-line treatment for chronic hepatitis B (CHB) have been shown to partially restore the antiviral immunity of the patients. However, hepatitis B virus (HBV) related hepatocellular carcinoma (HCC) patients have a relatively longer duration of HBV infection and lower level of HBV DNA. Whether NAs treatments have a different effect on their immune repertoires between CHB and HCC patients remains to be determined.
No takes yet. Share an insight, caveat, or question.
Shen et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: